Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), completed a series of equity transactions on July 15, 2026, under a Rule 10b5-1 trading plan adopted in February 2026. The transactions included the acquisition of 4,351 shares through option exercise and the sale of 4,351 shares at a weighted average price of $23.3808 per share, alongside the grant of 4,351 stock options with an exercise price of $3.98. These insider movements reflect routine capital allocation activity under a predetermined trading schedule established months earlier.
Key Points
- NASDAQ: GLUE
- Chief Operating Officer Jennifer Champoux executed stock sales and option grants on July 15, 2026
- 4,351 shares sold at weighted average price of $23.3808; 4,351 shares acquired through option exercise at $3.98 per share; 4,351 stock options granted with $3.98 exercise price
- All transactions conducted under a Rule 10b5-1 trading plan adopted February 19, 2026, representing pre-arranged trading activity
Monte Rosa Therapeutics Executive Equity Activity Overview
Monte Rosa Therapeutics, Inc. operates as a biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. The company's business model centers on identifying and validating novel drug targets and developing therapeutic candidates designed to address unmet medical needs in oncology. As a NASDAQ-listed entity, Monte Rosa Therapeutics maintains transparency regarding insider ownership changes through regulatory disclosures, allowing investors to monitor management shareholding activity and alignment with company interests.
The equity transactions disclosed by Jennifer Champoux on July 16, 2026, reflect routine capital management activities by a senior executive. Following the completion of these transactions, Champoux's direct beneficial ownership of Monte Rosa Therapeutics common stock totaled 62,371 shares. The filing demonstrates ongoing engagement by company leadership in equity participation, with both acquisition and disposition activity occurring simultaneously under the established trading framework.
Structured Trading Plan Framework and Timing
All transactions executed by Champoux on July 15, 2026, were conducted pursuant to a Rule 10b5-1 trading plan that the reporting person adopted on February 19, 2026. Rule 10b5-1 trading plans allow company insiders to establish predetermined, written instructions for buying or selling securities during periods when trading might otherwise be restricted due to access to material non-public information. The adoption of such a plan by a Chief Operating Officer demonstrates adherence to insider trading compliance protocols and provides investors with transparency regarding the prearranged nature of the equity activity.
The February adoption date indicates that these July transactions were scheduled months in advance, meaning the share sales and acquisitions did not represent reactive decisions based on interim company developments or near-term market conditions. This structure is designed to address regulatory concerns regarding insider trading while allowing executives to manage personal investment portfolios systematically. The timing framework reinforces that these movements reflect predetermined capital allocation strategy rather than opportunistic or discretionary trading responses.
Share Acquisition Through Stock Option Exercise
Champoux acquired 4,351 shares of Monte Rosa Therapeutics common stock on July 15, 2026, through the exercise of stock options at a strike price of $3.98 per share. Following this acquisition, her total direct beneficial ownership of common shares increased to 66,722 shares. This option exercise activity is distinct from the simultaneous share sale transaction and represents the conversion of derivative securities into direct equity ownership in the company.
The stock options exercised carry a vesting schedule whereby 25% of the underlying shares vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, contingent upon Champoux's continued service with the company. This graduated vesting structure is designed to encourage retention of executive talent and align long-term compensation with sustained company leadership. The exercise of these options during the reporting period reflects Champoux's decision to convert exercisable equity rights into direct common stock holdings.
Equity Sale Transaction Details and Pricing
On the same date as the option exercise, Champoux sold 4,351 shares at a weighted average price of $23.3808 per share, generating proceeds from the disposition of existing holdings. The disclosure indicates that these shares were sold in multiple separate transactions, with individual sale prices ranging from $22.83 to $23.71 per share, inclusive. This price range reflects market execution across multiple trades during the trading day, with the weighted average representing the blended price across the total transaction volume sold by the reporting person.
Following the share sale, Champoux's direct beneficial ownership of common stock declined to 62,371 shares. The company undertakes in the disclosure to provide, upon request by the company, any security holder, or the Securities and Exchange Commission staff, full documentation of the number of shares sold at each specific price within the reported range. This commitment to detailed transaction transparency aligns with regulatory expectations for insider trading disclosures and supports verification of pricing accuracy by relevant authorities.
New Stock Option Grant and Exercise Price
In connection with the July 15, 2026 transactions, Champoux received a grant of 4,351 stock options with an exercise price of $3.98 per share. The expiration date for these options is June 3, 2034, providing an eight-year window for exercise rights. Following the grant, Champoux's total beneficial ownership of derivative securities in the form of stock options reached 26,947 options. The $3.98 exercise price represents the valuation at which Champoux has the contractual right to purchase additional common shares during the option term.
The vesting structure for these newly granted options follows the same 25% immediate vesting (as of May 28, 2025) plus 36 monthly installments pattern documented in the disclosure. This consistent vesting framework across option grants is typical for executive compensation arrangements at public biopharmaceutical companies and reinforces retention incentives over a multi-year service period. The grant size of 4,351 options aligns with the simultaneous share acquisition and disposition activity, suggesting coordinated compensation and capital management planning by the company.
Beneficial Ownership Position After Transaction Settlement
Following completion of all transactions on July 15, 2026, and reported on July 16, 2026, Jennifer Champoux maintained direct beneficial ownership of 62,371 shares of Monte Rosa Therapeutics common stock. Her direct beneficial ownership of stock options increased to 26,947 options with the new grant. The filing confirms that all ownership interests are held in direct form, with no indirect beneficial ownership arrangements or holdings through intermediary entities disclosed in this reporting period.
The relatively modest adjustment in share count—declining from 66,722 to 62,371 shares after the option exercise and sale—reflects the offsetting nature of the simultaneous transactions on the same trading day. Champoux's continued direct equity participation in Monte Rosa Therapeutics, representing ongoing financial stake alignment with company performance, remains substantial following these activities. The disclosure provides investors with a clear snapshot of executive ownership position at a specific point in time and supports monitoring of potential management shareholding trends.
Regulatory Compliance and Insider Trading Plan Governance
The use of a Rule 10b5-1 trading plan represents a recognized compliance mechanism for insider trading regulations and reflects adherence to securities law requirements governing officer and director transactions. By establishing the plan in February 2026, approximately five months before the July execution, Champoux created documented evidence of predetermined trading intentions that are insulated from accusations of trading on material non-public information. This regulatory framework is widely adopted by public company executives and senior management across multiple industries as a best practice for transparent capital management.
The filing status as a Chief Operating Officer places Champoux in a position of significant company influence and responsibility. Her compliance with insider trading procedures and transparent disclosure of all equity movements supports investor confidence in management governance practices. The detailed documentation of transaction prices, dates, and underlying security information demonstrates adherence to Exchange Act reporting obligations and provides market participants with comprehensive visibility into insider equity activity at Monte Rosa Therapeutics.
Investment Considerations for Shareholders
Insider transactions by company officers, particularly those executed under predetermined trading plans, provide shareholders with information regarding management confidence levels and capital allocation priorities. When executives simultaneously exercise options and sell shares at higher market prices than the exercise cost, the pattern may reflect routine portfolio management or rebalancing strategies rather than investment thesis changes. Investors analyzing insider activity should consider the predetermined nature of trading plan transactions and distinguish such systematic activity from discretionary open-market trades that may signal more immediate management sentiment shifts.
The weighted average sale price of $23.3808 per share, compared to the $3.98 option exercise price, reflects a significant appreciation in share value over the vesting period. This spread represents substantial gains on option compensation for the reporting period. Shareholders monitoring insider ownership positions may use such filings to track whether management holdings are increasing or decreasing over time and assess implications for executive stake alignment with long-term shareholder value creation objectives. The disclosure provides transparent data for such analysis without requiring speculation regarding underlying executive intent.
Monte Rosa Therapeutics Market Context and Executive Compensation Framework
Monte Rosa Therapeutics operates in the competitive biopharmaceutical sector, where executive compensation packages typically include base salary, performance bonuses, and equity incentives in the form of stock options and restricted stock units. The structure disclosed in this report, combining option exercises with immediate sales and new option grants, is consistent with standard compensation and equity management practices at publicly traded biotechnology companies. The company's approach to executive incentive design reflects industry norms aimed at aligning management interests with shareholder outcomes while providing liquidity and portfolio diversification opportunities for senior leadership.
The filing does not disclose the aggregate value of compensation or broader context regarding Champoux's total compensation package from Monte Rosa Therapeutics. Investors seeking comprehensive information regarding executive compensation at the company would need to reference proxy statements and other periodic disclosures that provide detailed breakdowns of salary, bonuses, option grants, and other benefits provided to named executive officers. The insider trading report provides transactional detail regarding equity movements but does not encompass full compensation disclosure requirements applicable under other regulatory frameworks.



Please wait processing your request...